GlaxoSmithKline announced the results of three studies evaluating lapatinib - an oral, small molecule inhibitor of HER2 - in various breast cancer settings, either in combination with other targeted therapies or as a monotherapy. Use of lapatinib in these settings is investigational. Results from these studies are being presented during the annual American Society of Clinical Oncology (ASCO) meeting in Chicago, May 30 - June 3, 2008.
More...
Linear Mode
